Hepatology International最新文献

{"title":"Comments on: Functional cure with new antiviral therapy for hepatitis B virus: a systematic review and meta-analysis.","authors":"Meng-Yuan Shen, Ze-Jiong Li, Dan-Dan Feng, Jian-Nong Wu","doi":"10.1007/s12072-025-10869-5","DOIUrl":"10.1007/s12072-025-10869-5","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of pediatric living donor liver transplantation using steatotic grafts: expanding the donor pool for rising MASLD prevalence.","authors":"Jie Li, Yixiao Pan, Yefeng Lu, Xinye Zhu, Jiahao Ge, Siyuan Tang, Jie Zhao, Mei Long, Xiaochen Bo, Yiqing Zhang, Ping Wan, Kang He, Taihua Yang, Qiang Xia","doi":"10.1007/s12072-025-10851-1","DOIUrl":"https://doi.org/10.1007/s12072-025-10851-1","url":null,"abstract":"<p><strong>Background: </strong>Pediatric living donor liver transplantation (PLDLT) is a life-saving option for children with end-stage liver diseases. However, the growing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) raises concerns regarding the use of steatotic donor grafts, particularly in vulnerable pediatric populations.</p><p><strong>Methods: </strong>This study retrospectively investigated the impact of steatotic liver grafts on post-transplant outcomes in PLDLT recipients. 905 PLDLT recipients at Renji Hospital, Shanghai Jiao Tong University School of Medicine, from January 2019 to December 2021 were screened using computed tomography (CT) liver/spleen ratio and classified into three groups according to the degree of steatosis. This study evaluated early liver function, post-transplant complications, and long-term graft and patient survival.</p><p><strong>Results: </strong>Recipients in the moderate-to-severe group exhibited higher incidence of rejection. However, there were no significant differences in early liver function and the 1-year and 3-year graft and patient survival among three groups.</p><p><strong>Conclusions: </strong>The use of steatotic livers in PLDLT can be considered a viable option, with careful donor selection and vigilant postoperative management. These findings highlight the potential of MASLD as an expansion of the donor pool owing to its rising incidence and offer new insights into optimizing pediatric transplant outcomes while addressing the scarcity of suitable donor organs.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144659100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatitis C virus incidence trend and its risk factors among people who inject drugs in Hai Phong, Vietnam.","authors":"Hong Thi Tran, Huong Thi Duong, Khue Minh Pham, Binh Thanh Nguyen, Roselyne Vallo, Morgana D'Ottavi, Giang Thi Hoang, Vinh Hai Vu, Oanh Thi Hai Khuat, Thanh Tuyet Thi Nham, Duc Quang Nguyen, Catherine Quillet, Delphine Rapoud, Philippe Van de Perre, Jonathan Feelemyer, Laurent Michel, Didier Laureillard, Don Des Jarlais, Jean-Pierre Moles, Nicolas Nagot","doi":"10.1007/s12072-025-10856-w","DOIUrl":"10.1007/s12072-025-10856-w","url":null,"abstract":"<p><strong>Background: </strong>HCV incidence among people who inject drugs (PWID) remains unacceptably high. Using the data from the DRIVE study, we aimed to describe HCV incidence trends and investigate its associated risk factors among PWID in Hai Phong, Vietnam.</p><p><strong>Methods: </strong>Active PWID were recruited through 3 annual respondent-driven sampling (RDS) surveys; part of them were included in the study cohorts. HCV seroincidence was calculated for PWID participating in multiple surveys (recaptures) or in cohorts. A nested case-control design was used for risk factor analysis. Controls were matched to HCV seroconversion cases on age, sex, cohort participation and HCV seroconversion visit. Risk factors were measured over the period preceding the HCV seroconversion visits.</p><p><strong>Results: </strong>There were 83 HCV seroconversions during 844 person-years in 540 included participants. The overall HCV incidence was 9.8/100 person-years (95% CI 7.9-12.2). HCV incidence decreased over follow-up time and was particularly high among PWID living with HIV (PLWH), i.e., 37.2/100 person-years (95% CI 26.4-52.3). HIV infection (OR = 10.0, 95% CI 6.8-16.2) and active heroin injection (OR: 3.2, 95% CI 2.3-4.8) were associated with a higher risk of HCV seroconversion for cohort participants. Among RDS recaptures, living with a sexual partner and currently using methadone had opposite effects on HCV incidence, OR = 2.9, 95% CI 2.2-4.3 and OR = 0.4, 95% CI 0.3-0.5, respectively.</p><p><strong>Conclusion: </strong>HCV incidence among PWID in Hai Phong was still 5 times higher than the WHO target for elimination. Along with strengthened HCV prevention programs, affordable HCV treatment should be made available for PWID to reach the elimination goal.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144659099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative effectiveness of tirzepatide versus bariatric metabolic surgery in adults with metabolic-associated steatotic liver disease and obesity: a multi-institutional propensity score-matched study.","authors":"Jheng-Yan Wu, Yu-Min Lin, Wan-Hsuan Hsu, Ting-Hui Liu, Ya-Wen Tsai, Po-Yu Huang, Min-Hsiang Chuang, Tsung Yu, Chih-Cheng Lai","doi":"10.1007/s12072-025-10857-9","DOIUrl":"https://doi.org/10.1007/s12072-025-10857-9","url":null,"abstract":"<p><strong>Objective: </strong>This study compared the clinical outcomes of tirzepatide versus bariatric metabolic surgery (BMS) in adults with metabolic-associated steatotic liver disease (MASLD) and obesity.</p><p><strong>Methods: </strong>A retrospective cohort analysis was conducted using the TriNetX Global Collaborative Network. Patients with MASLD and obesity were stratified into tirzepatide and BMS groups. Propensity score matching (PSM) was used to balance baseline characteristics. The primary outcome was a composite measure including all-cause mortality, major adverse cardiovascular events (MACE), major adverse kidney events (MAKE), and major adverse liver outcomes (MALO).</p><p><strong>Results: </strong>After PSM, 6199 patients were classified into each group (tirzepatide and BMS). The tirzepatide group showed a lower risk of the composite outcome, with an incidence rate of 1.9 per 100 person-years compared to 3.5 per 100 person-years in the BMS group (HR 0.47; 95% CI 0.36-0.61). Additionally, the incidence of all-cause mortality was lower in the tirzepatide group (0.4 vs. 0.9 per 100 person-years, HR 0.36, 95% CI 0.21-0.63). Similarly, MAKEs occurred less frequently in the tirzepatide group (0.7 vs. 1.8 per 100 person-years, HR 0.32, 95% CI 0.21-0.49), as did MALOs (0.8 vs. 2.0 per 100 person-years, HR 0.32, 95% CI 0.22-0.48).</p><p><strong>Conclusions: </strong>Tirzepatide offers better clinical outcomes compared to BMS in adults with MASLD and obesity, significantly reducing all-cause mortality as well as kidney- and liver-related complications. These findings highlight tirzepatide as a promising alternative to BMS, offering a less invasive approach with potential benefits in managing MASLD and obesity. This study found that tirzepatide, a medication used to treat obesity and metabolic conditions, led to better health outcomes than bariatric surgery in adults with metabolic-associated steatotic liver disease (MASLD) and obesity. Patients treated with tirzepatide had lower risks of death and serious heart, kidney, and liver complications, suggesting it may be a safer, less invasive alternative to surgery.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing therapeutic plasma exchange in Wilson disease-related liver failure: toward precision bridging strategies.","authors":"Qi Xu, Yuwan Gao","doi":"10.1007/s12072-025-10867-7","DOIUrl":"https://doi.org/10.1007/s12072-025-10867-7","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144600169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Letter to the Editor \"Hepatic irAE, ICI continuation, and survival: need for robust evidence beyond initial observations\".","authors":"Tatsuo Kanda, Kaori Matsumoto, Shuntaro Obi, Hitoshi Mochizuki, Masao Omata","doi":"10.1007/s12072-025-10868-6","DOIUrl":"https://doi.org/10.1007/s12072-025-10868-6","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: \"Hepatic immune-related adverse event increased the overall survival of patients with malignancies treated with immune checkpoint inhibitors\".","authors":"Ruo-Lan Lei, Lin-Rong He, Xiao-Ying Zhao, Yu Jiang","doi":"10.1007/s12072-025-10861-z","DOIUrl":"10.1007/s12072-025-10861-z","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on \"Preoperative carbohydrate loading reduces perioperative insulin resistance and hastens functional recovery of remnant liver after living donor hepatectomy: an open-label randomized controlled trial\".","authors":"Meng-Yuan Shen, Rong Zhou, Jian-Nong Wu","doi":"10.1007/s12072-025-10864-w","DOIUrl":"https://doi.org/10.1007/s12072-025-10864-w","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stem cells therapies for liver diseases: for current practice and future goals.","authors":"Yunbo Xie, Ziying Zhang, Yuefei Pan, Fu-Sheng Wang","doi":"10.1007/s12072-025-10835-1","DOIUrl":"https://doi.org/10.1007/s12072-025-10835-1","url":null,"abstract":"<p><strong>Background: </strong>Stem cell therapy has emerged as a promising approach for treating severe chronic liver diseases, including decompensated liver cirrhosis (DLC) and liver failure(LF), with mesenchymal stem cells (MSCs) being the most extensively investigated cell type in both preclinical and clinical trials.</p><p><strong>Objective: </strong>To summarize the research progress in clinical studies of stem cells therapy for chronic liver diseases, providing a comprehensive overview of current knowledge.</p><p><strong>Methods: </strong>Research on stem cell therapy for liver diseases was searched from databases such as PubMed, Web of Science, Google Scholar, and ClinicalTrials.gov.</p><p><strong>Results: </strong>As of March 31, 2025, over 110 clinical trials investigating stem cell therapies for chronic liver diseases have been registered, predominantly in Phase I and Phase II stages. MSCs derived from umbilical cord, bone marrow, or adipose tissue representing the primary cellular sources. Stem cell therapy has demonstrated favorable safety profiles in the treatment of liver diseases. Concurrently, emerging evidence highlights its preliminary efficacy in enhancing patient survival rates and promoting hepatic functional recovery. However, challenges remain, such as inconsistent efficacy across trials, the absence of standardized protocols, and unresolved safety concerns. Emerging technologies, including stem cell-derived exosomes, gene-edited stem cells, and 3D liver organoids, show promising preclinical potential but require further validation.</p><p><strong>Conclusion: </strong>Stem cell therapy holds great potential for liver disease treatment. Although not yet a mainstream clinical option, continuous research may lead to effective, widely applicable treatments in the future.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatic irAE, ICI continuation, and survival: need for robust evidence beyond initial observations.","authors":"Lining Huang, Liang Wang, Zhiming Qiao","doi":"10.1007/s12072-025-10853-z","DOIUrl":"https://doi.org/10.1007/s12072-025-10853-z","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}